Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTED: Daclizumab HYP Extension in RRMS
NCT01051349Phase 2Completed
- Sponsor
- Biogen
- Start
- Mar 2010
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Mar 2010; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01051349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051349.